Teva's new MS trial for laquinimod causes Active slump
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries said it will be conducting an additional clinical trial of laquinimod before filing for approval of the multiple sclerosis drug candidate. Teva licensed rights to laquinimod from Active Biotech, which saw its share price slump by 27% to close at SEK20.30 on the news which was relayed during Teva's Q3 conference call on 2 November.